Fingerprint
Dive into the research topics of 'Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: A phase I and pharmacokinetic study in patients with advanced cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically